Asher Rubin

Asher Rubin


Email asher.rubin@​

Phone +1 410 659 2777

Fax +1 410 659 2701

Practice groupCorporate & Finance

As Global Head of our Life Sciences industry group, Asher Rubin has spent the past several years working with clients on some of the most exciting new technologies in the life sciences industry, such as CAR-T therapies, checkpoint inhibitors, co-stimulatory proteins, companion diagnostics, digital health technologies, ultra-orphan drugs, and gene therapies.

Asher developed his extensive industry knowledge over a period of more than 15 years, beginning with his role as in-house counsel and ultimately general counsel of a publicly traded, fully integrated pharmaceutical company.

Currently, Asher represents both private and publicly traded businesses, academic medical centers, inventors, and venture capital and private equity funds in a wide variety of transactions. He has comprehensive knowledge of the full spectrum of the life sciences sector: pharmaceuticals, biotechnology, medical devices, medical technology, digital health, and health services.

Asher has successfully negotiated and completed a range of life sciences transactions, with a particular focus on complex collaborative arrangements. Additionally, he regularly advises clients on venture capital financing, initial public offerings, follow-on financing, mergers and acquisitions, licensing transactions, joint ventures, co-promotion agreements, manufacturing arrangements, royalty acquisitions and divestitures, structured-finance arrangements, and sponsored research.

With six years of service as in-house counsel, he provides practical guidance to CEOs, CFOs, GCs, and other executives on their everyday legal matters, which include board governance, compensation, and employment matters. He regularly serves as a senior advisor to in-house counsel and as an outside general counsel for clients with limited in-house resources.

"Asher is an outstanding attorney who has been practicing at the top-tier of life sciences corporate and legal affairs for over a decade. He brings not only his exceptional talents, but also a very current perspective on a range of important life sciences issues and solutions that are highly relevant to our multi-vertical commercialization strategy."

CEO at a client organization

Awards and recognitions


Life Sciences: Corporate/Commercial (USA)
Chambers Global


Life Sciences: Corporate/Commercial (Nationwide)
Chambers USA


Corporate/M&A (Maryland)
Chambers USA


Acritas Star
Acritas Stars Independently Rated Lawyers


Healthcare: Life Sciences, Hall of Fame
Legal 500 US


Healthcare: Life Sciences, Leading Lawyer
Legal 500 US


Life Sciences Star
LMG Life Sciences


Industry focus: Healthcare: life sciences, Recommended
Legal 500 US


Mergers & Acquisitions Law
The Best Lawyers in America

Education and admissions


J.D., University of Maryland, Francis King Carey School of Law, The William O. Cunningham Award for Exceptional Service to the School of Law, 1995

B.A., Duke University, 1992


Member, Maryland State Bar Association

Member, American Corporate Counsel Association, Baltimore Chapter

Member, American Society of Corporate Secretaries & Governance Professionals

Member, General Counsel Committee, Biotechnology Industry Organization (BIO)

Bar admissions and qualifications


Related knowledge

3D Printing

Representative experience

Representing Intellia Therapeutics in its research collaboration and license agreement with GEMoaB to develop allogeneic cellular immunotherapies for treating cancers and inflammatory diseases.

Representing TESARO in its US$101m Series B financing, its IPO, and all of its follow-on equity financings and US$165m notes financing.

Representing TESARO in connection with its acquisition of rights to its niraparib PARP inhibitor, ALK inhibitor, and checkpoint inhibitor programs.

Representing TESARO in its collaboration and license agreement with Janssen Biotech involving niraparib for the treatment of prostate cancer.

Representing TESARO in its exclusive licensing agreement with Takeda for the commercialization and clinical development of niraparib in Japan.

Representing of Amplimmune, Inc. in connection with its sale for up to US$500m to AstraZeneca.

Representing MGI PHARMA, Inc. in its sale to Eisai Co., Ltd. in an all-cash tender offer, with a total transaction value of approximately US$3.9bn.

Representing New Enterprise Associates in connection with the formation and Series A financing of TESARO.

Representing New Enterprise Associates and Apple Tree Partners in several venture capital financings of companies at various stages of development.

Representing the University of Pennsylvania in connection with its exclusive license and collaboration of CAR-T technologies to Novartis.

Representing the University of Pennsylvania on its US$100m Series A financing round for Tmunity, a cutting-edge cell therapy using CRISPR to modify immune cells.

Representing Merck & Co., Inc., in its sale of its biomanufacturing network to Fujifilm.

Representing Immune Design Corp., in connection with its exclusive licenses to a pharmaceutical company for food allergies and HSV.

Representing Braeburn Pharmaceuticals on its US$110m mezzanine round of financing led by Wellington Management Company.

Representing GenVec on its acquisition by Intrexon Corp.

Representing Incyte Corp. in its license and collaboration agreement with MacroGenics relating to an anti-PD-1 antibody.

Representing NextCure in its license and sponsored research agreements with Yale University.

Representing NextCure in connection with its formation and US$67m Series A financing.

Representing Vivus on its acquisition of Pancreaze from Janssen Pharmaceuticals and its acquisition of Willow BioPharma.

Representing Fibrocell Science, Inc. on their acquisition by Castle Creek Pharmaceutical, Inc. with a total transaction value of approximately US$63.3m.

Representing Optinose on their licensing agreement with Onzetra Xsail.

Loading data